Skip to main content

Advertisement

Table 3 Positivity of different triage tests for histologically negative (NEG), CIN1, CIN2, CIN3, and CC

From: Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping

  NEG (n = 158) % (95% CI) CIN1 (n = 79) % (95% CI) CIN2 (n = 26) % (95% CI) CIN3 (n = 50) % (95% CI) CC (n = 3) % (95% CI)
HPV16/18+ 72.2 (64.6–78.6) 68.4 (57.1–77.8) 65.4 (44.3–81.8) 60.0 (45.5–72.9) 100
ASCUS+ 30.4 (23.6–38.1) 51.9 (40.7–62.9) 61.5 (40.7–78.9) 58.0 (43.6–71.2) 0
LSIL+ 25.9 (19.7–33.4) 41.8 (31.2–53.1) 61.5 (40.7–78.9) 50.0 (36.0–64.0) 0
HSIL+ 3.2 (1.3–7.4) 6.3 (2.6–14.6) 19.2 (7.7–40.4) 34.0 (21.9–48.6) 0
S5 at 3.7 cutoff 27.2 (20.8–34.8) 26.6 (17.9–37.6) 50.0 (30.5–69.5) 66.0 (51.4–78.1) 100
S5 at 0.8 cutoff 57.6 (49.7–65.4) 64.6 (53.2–74.5) 73.1 (51.7–87.3) 92.0 (79.9–97.1) 100
  1. ASCUS+ atypical squamous cells of undetermined significance or worse, HSIL+ high-grade squamous intraepithelial lesion or worse, LSIL+ low-grade squamous intraepithelial lesion or worse, NEG histologically negative, CIN cervical intraepithelial neoplasia (of grades 1, 2, and 3), CC cervical cancer